Literature DB >> 31967671

Seizures in patients with cancer.

L Nicolas Gonzalez Castro1,2, Tracey A Milligan2.   

Abstract

Seizures are common in patients with cancer and either result from brain lesions, paraneoplastic syndromes, and complications of cancer treatment or are provoked by systemic illness (metabolic derangements, infections). Evaluation should include a tailored history, neurologic examination, laboratory studies, neuroimaging, and electroencephalogram. In unprovoked seizures, antiepileptic drug (AED) treatment is required, and a nonenzyme-inducing AED is preferred. Treatment of the underlying cancer with surgery, chemotherapy, and radiation therapy also can help reduce seizures. Benzodiazepines are useful in the treatment of both provoked seizures and breakthrough epileptic seizures and as first-line treatment for status epilepticus. Counseling for safety is an important component in the care of a patient with cancer who has seizures. Good seizure management can be challenging but significantly improves the quality of life during all phases of care, including end-of-life care.
© 2020 American Cancer Society.

Entities:  

Keywords:  antiepileptic drugs; brain tumor; cancer; epilepsy; seizures

Year:  2020        PMID: 31967671     DOI: 10.1002/cncr.32708

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

Review 1.  Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity.

Authors:  Luis Nicolas Gonzalez Castro; Jorg Dietrich
Journal:  Neurooncol Pract       Date:  2020-11-29

2.  Glioblastoma in Patients With Multiple Sclerosis.

Authors:  Jillian M Berkman; Vihang Nakhate; L Nicolas Gonzalez Castro
Journal:  Neurohospitalist       Date:  2022-06-08

3.  Identification of Hub Genes of Mesio Temporal Lobe Epilepsy and Prognostic Biomarkers of Brain Low-grade Gliomas Based on Bioinformatics Analysis.

Authors:  Jian Xu; Mingqiang Sun; Yuanyuan Wang; Anmu Xie; Jian Gao
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.